Khvorova A.,RXi Pharmaceuticals |
Wolfson A.,University of Massachusetts Medical School
Nature Biotechnology | Year: 2012
An additional layer of RNA regulation in which RNAs encoded by genes and pseudogenes compete for microRNAs could offer new opportunities for oligonucleotide therapeutics. © 2012 Nature America, Inc. All rights reserved. Source
News Article | May 5, 2015
The report “Liver Fibrosis - Pipeline Review, H2 2014” provides comparative analysis on the therapeutic development for Liver Fibrosis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/liver-fibrosis-pipeline-review-h2-2014-market-report.html . Companies discussed in this Liver Fibrosis – Pipeline Review, H2 2014 report include ACROVIS biostructures GmbH, Advinus Therapeutics Ltd., Angion Biomedica Corp., BiOrion Technologies B.V., Celgene Corporation, Digna Biotech, S.L., FibroGen, Inc., Galectin Therapeutics, Inc., Genfit SA, GenKyoTex S.A., Gilead Sciences, Inc., GNI Group Ltd., La Jolla Pharmaceutical Company, LG Life Sciences, Ltd., Nitto Denko Corporation, Pfizer Inc., Pharmaxis Limited, Promedior, Inc., Promethera Biosciences S.A., ProMetic Life Sciences Inc., RXi Pharmaceuticals Corporation, Silence Therapeutics plc, TCM Biotech International Corp and Virobay Inc. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Drug Profiles mentioned in this report are AbyD-3263, ANG-3281, ANG-3298, ANG-4011, BOT-162, BOT-191, CC-539, CC-90001, CIGB-500, CT-140, DB-036, disitertide, Drugs to Inhibit NADPH Oxidase for Influenza and Liver Fibrosis, F-351, FG-3019, GCS-100, GFT-505, GKT-137831, GM-CT-01, GM-CT-02, GR-MD-01, GR-MD-02, HepaStem, KBP-7018, KW-0, LC-280126, LJPC-201, melittin, ND-L02s0201, NPLC-0393, P-17, PBI-4050, PRI-724, PRM-151, PXS-4728A, PXS-5033-A, RNAi Oligonucleotide for Hepatocellular Carcinoma, Ischemia Reperfusion Injury and Fulminant Fibrosis, RXI-209, simtuzumab, Small Molecule for Liver Fibrosis, Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis, Small Molecule to Inhibit NOX 1 and 4, Small Molecules for Liver Diseases, Small Molecules to Inhibit EGFR for Gastrointestinal Disorders, Stem Cell Therapy for Liver Fibrosis and Liver Diseases, Synthetic Peptide to Inhibit RSK for Fibrosis and Oncology, TCM-808FB, TGFTX-4 Program, VBY-376 and VBY-825. Order a purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=239901 . (This is a premium report priced at US$2000 for a single user License.) Number of Products under Development for Liver Fibrosis, H2 2014 12 Number of Products under Development for Liver Fibrosis - Comparative Analysis, H2 2014 13 Number of Products under Development by Companies, H2 2014 15 Number of Products under Development by Companies, H2 2014 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H2 2014 18 Comparative Analysis by Clinical Stage Development, H2 2014 19 Comparative Analysis by Early Stage Development, H2 2014 20 Number of Products under Development for Liver Fibrosis, H2 2014 12 Number of Products under Development for Liver Fibrosis - Comparative Analysis, H2 2014 13 Number of Products under Development by Companies, H2 2014 14 Number of Products under Investigation by Universities/Institutes, H2 2014 17 Comparative Analysis by Clinical Stage Development, H2 2014 19 Comparative Analysis by Early Stage Products, H2 2014 20 Assessment by Monotherapy Products, H2 2014 49 Number of Products by Top 10 Targets, H2 2014 50 Number of Products by Stage and Top 10 Targets, H2 2014 50 Number of Products by Top 10 Mechanism of Actions, H2 2014 53 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 53 Number of Products by Top 10 Routes of Administration, H2 2014 56 Number of Products by Stage and Top 10 Routes of Administration, H2 2014 57 Number of Products by Top 10 Molecule Types, H2 2014 58 Number of Products by Stage and Top 10 Molecule Types, H2 2014 59 Explore more reports on Therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics . About Us: RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
News Article | June 11, 2015
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/q5b3gf/scar_pipeline) has announced the addition of the "Scar - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Scar, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Scar and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
News Article | March 27, 2015
New study shows you commercial prospects for leading ophthalmic drug companies What does the future hold for top companies in the pharma ophthalmic industry? Visiongain's brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there. Our 242-page report provides 185 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market. Forecasts from 2015-2025 and other analyses show you commercial prospects Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of 3 exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including: • Dr Leigh Hsu, Vice President, Corporate Development & Strategy, Lpath • Dan Myers, President and CEO, Alimera Sciences • Vanda Pharmaceuticals To see a report overview please email Sara Peerun on firstname.lastname@example.org Discover sales predictions for the world market and submarkets Overall we estimate the world revenue for ophthalmic drugs reached $21,513m in 2014. We predict revenue growth from 2015 to 2025. Increasing prevalence of ophthalmic diseases due to demographic trends, expansion of healthcare in developing economies, relatively rich pipelines especially in retinal disorders, large unmet needs in the glaucoma and dry eye markets are set to drive sales in the ophthalmic drugs market to 2025. Along with revenue prediction for the overall world market, you see forecasts to 2025 for these five submarkets: • Retinal disorders drugs • Allergic, inflammatory and infective drugs • Glaucoma drugs • Dry eye drugs • Other ophthalmic drugs In addition we provide market attractiveness forecast analysis for the leading segments in 2019 and 2025. You gain competitive advantages by understanding the dynamics, opportunities and challenges facing the ophthalmic drugs market. Leading companies and potential for market growth Our ophthalmic leader series report shows you a ranking for the top 25 ophthalmic drug manufacturers based on revenues and R&D progress. Additionally, the report provides you with in-depth analysis and profiles for the top 10 leading companies in the ophthalmic drugs market including: • Novartis • Allergan • Roche • Valeant • Regeneron • Santen • Bayer • Pfizer • Senju • Akorn A company profile gives you the following information: • Total ophthalmic drugs revenue forecasts to 2025 • Revenue forecasts for individual leading ophthalmic drugs to 2025 • Market share in the global ophthalmic drugs market forecast to 2025 • Ophthalmic drugs revenue rankings • Recent financial results • Ophthalmic drugs pipeline analysis • SWOT analysis • Discussion of a company's activities and outlook • Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures Moreover, our report provides information on 27 additional leading companies in the ophthalmic drugs market. You see outlooks for a wide range of companies, from multinationals to emerging specialists in the eye disorders field. Find developments for treating visual disorders and sight loss. See revenue forecasts for products How will leading ophthalmic drugs perform to 2025 at world level? Our study forecasts sales of more than 25 products, including these brands: • Lucentis • Eylea • Avastin • Restasis • Lumigan and Ganfort • Xalatan/Xalacom • Travatan/Travatan Z and DuoTrav • Alphagan/Alphagan P and Combigan • Refresh brand products • Pataday • Vigamox Discover how high revenues can go. You see what's happening, understanding trends, challenges and opportunities. As well as finding drugs that will likely achieve the most success. What issues will affect the ophthalmic drugs market? Our new report discusses issues and events affecting the ophthalmic drugs market. You will find discussions, including qualitative analyses: • Increasing demand for ophthalmic drugs due to demographic trends • A strong R&D pipeline • Patent expiry and generic competition • Growth areas such as wet AMD and dry eye • Advances in topical drug delivery • Sustained-release ocular implants • Pricing and reimbursement issues You will see discussions of technological, commercial, political and economic matters, with emphasis on the competitive landscape and business outlooks. To see a report overview please email Sara Peerun on email@example.com How the Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 report helps you: In summary, our 242-page report gives you the following knowledge: • Revenues forecast to 2025 for the world ophthalmic drugs market and 5 submarkets - discover the industry's prospects, finding promising places for investments and revenues • Market attractiveness forecast analysis of ophthalmic drugs submarkets in 2019 and 2025 - discover potential of individual submarkets • Ophthalmic drug revenue forecasts to 2025 for the leading 10 companies - Novartis, Allergan, Roche, Valeant, Regeneron, Santen, Bayer, Pfizer, Senju and Akorn • Assessment of 37 leading companies - hear about products, pipelines, results and strategies, and recent developments • Revenue forecasts to 2025 for more than 25 leading ophthalmic drugs - discover their revenue potentials. • Discussion of what stimulates and restrains companies and the market - you assess challenges and strengths • Understanding of competition and opportunities - you see what affects that industry, learning what shapes its future • Prospects for established firms and those seeking to enter the market - you explore needs, practices and outlooks for success • View interviews with market experts - gain exclusive market insights You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence. We give independent analysis from our primary and secondary research. You will receive business intelligence found only in our study, seeing where prospects are lucrative and growth is likely. With our report you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions, saving you time and getting you recognition for commercial insight. Discover technological and commercial prospects from 2014 by ordering now Visiongain's study is for everybody needing commercial analyses for the ophthalmic drugs market and leading companies. You find data, trends and predictions. Please order our report now. To request an exec summary of this report please email Sara Peerun at firstname.lastname@example.org or call Tel: +44 (0) 20 7336 6100 Abbott Laboratories Abbvie Acucela Advanced Vision Research Aerie Pharmaceuticals Aerpio Therapeutics Akorn Pharmaceuticals Alcon Alimera Sciences Allergan Altheos Amakem Ampio Pharma AstraZeneca Aton Pharma Barr Laboratories Bausch and Lomb Bayer BioDiem BioInvent International Biovail Corporation Bristol-Myers Squibb Can-Fite BioPharma Chengdu Kanghong Pharmaceutical Ciba-Geigy Colby Pharmaceutical Company Daiichi Sankyo Eleven Biotherapeutics Eli Lilly and Company EyeGate Pharmaceuticals Gene Signal Genentech Genzyme GSK Icon Bioscience InSite Vision Inspire Pharmaceuticals ISTA Pharmaceuticals Kyorin Pharmaceutical Lpath MacuCLEAR MacuSIGHT, Inc. Merck & Co. MerLion Pharmaceuticals MSD K.K. Mylan Pharmaceuticals Mystic Pharmaceuticals Neurotech NicOx NovaBay Pharmaceuticals Novagali Pharma Novartis Novo Novo Nordisk Oakwood Laboratories OcuSciences Omeros Onyx Pharmaceuticals OphthaliX Ophthotech OPKO Health Ora Otsuka Pharmaceutical Oxford BioMedica OXiGENE Par Pharmaceutical Parke-Davis Pfizer Pharmacia Premacure Procter & Gamble pSivida Quark Pharmaceuticals Regeneron RetroSense Therapeutics Roche RXi Pharmaceuticals Sandoz Sanofi Santen Pharmaceutical Co. SARcode Bioscience Senju Pharmaceuticals Co., Ltd. Senju USA Inc. Shire Sirion Therapeutics Sirna Therapeutics Spark Therapeutics Symphony ViDA Teva ThromboGenics Valeant Pharmaceuticals Warburg Pincus LLC Warner-Lambert Watson Pharmaceuticals Wyeth Pharmaceuticals Other Organisations Mentioned in this Report A*STAR Institute for Infocomm Research (Singapore) American Academy of Ophthalmology (AAO) American Diabetes Association American Society of Retina Specialists (ASRS) Association for Research in Vision and Ophthalmology (ARVO) Council of Europe Emory University European Medicines Agency (EMA) Foundation Fighting Blindness (FFB) (US) Health Canada Institute of Experimental Medicine (Russia) Institute of Ocular Pharmacology, Texas A&M (US) Institute of Ophthalmology, University College London (UK) International Diabetes Federation Japan Patent Office (JPO) Mayo Clinic Ministry of Health, Labour and Welfare (MHLW) (Japan) Monash University National Eye Institute (NEI) (US) National Health Service (NHS) (UK) National Institute for Health and Care Excellence (NICE) (UK) NHS Scotland Novartis Institutes for BioMedical Research (NIBR) Novartis Venture Funds (NVF) (part of Novartis) Ophthalmology External Research Unit (part of Pfizer) Ophthrisi (GSK research unit) Rinat (Pfizer research unit) Texas Emerging Technology Fund Therapeutic Goods Administration (TGA) (Australia) Tokyo University of Science United Nations Department of Economic and Social Affairs University of Florida University of Kentucky University of Melbourne University of Michigan Upjohn US Food and Drug Administration (FDA) US Preventive Services Task Force (USPSTF) US Securities and Exchange Commission (SEC) World Health Organization (WHO) To see a report overview please email Sara Peerun on email@example.com
News Article | July 10, 2015
EyeGate Deals Treatment Rights to Valeant to Pay for Clinical Trials EyeGate Pharmaceuticals, a Waltham, MA-based company that has been seeking FDA approval for an eye disease drug for years, is sacrificing future worldwide rights to a treatment for uveitis to get enough money from drug behemoth Valeant Pharmaceuticals International to put the therapy back on regulatory track. In exchange for an undisclosed upfront cash payment and milestones, Valeant is getting worldwide commercial and manufacturing rights to EyeGate’s Phase 3 drug for anterior uveitis, an inflammatory condition that can lead to lost vision or permanent blindness. Valeant (NYSE: VRX), the pharmaceutical giant based in Canada that is known for its aggressive deal-making, also gains the same rights to the company’s system for delivering drugs into the eye, called EyeGate II. Valeant, which inked the agreement through an unnamed subsidiary, also received a last negotiation right to license EyeGate’s drug, EPG-437, for other indications. The drug is being studied for use in macular edema, dry eye, and cataract surgery, the company says in regulatory filings. EyeGate, founded 17 years ago with technology from the Bascom Palmer Eye Institute at the University of Miami, has been waiting to run a second Phase 3 trial of its uveitis treatment because the company needed more funding, the company says in a regulatory filing. The first Phase 3 trial showed that the treatment was about as effective as eye drops that are traditionally used as a treatment, though the EyeGate II device may need to be used less frequently, the company says in its regulatory filings. Its device, which is propped on a patient’s eye like a monocle, uses low-level electrical current to deliver a specific amount of the drug. Yet EyeGate’s cash coffers had apparently been drying up after an attempt to wrangle money from the public markets delivered less than expected. EyeGate, which is traded over the counter, filed paperwork in July 2014 to become a public company traded on Nasdaq. It intended to raise about $30 million. Even at the end of 2014, EyeGate had planned to use the proceeds of an IPO to finish the complementary Phase 3 trial on EPG-437 for uveitis by 2016, with the hope of regulatory approval by 2017. After cutting its pricing on the offering in half to between $6 and $8 per share in November, EyeGate sold fewer than 700,000 shares for $6 each in February on the over-the-counter market. After the IPO, EyeGate shifted its focus from uveitis until it could raise more money, according to regulatory filings. Instead, it planned to initiate and complete a Phase 2 trial on macular edema, a condition that swells an area of the retina after fluid and protein deposits collect. With Valeant, EyeGate has found a partner with enough cash to finish its clinical trials for uveitis, though it must give up the commercial and manufacturing rights worldwide. EyeGate would still receive milestone payments for the development, approval, and sales performance of the drug, as well as royalties based on net sales, the company said in a statement. EyeGate executives were not immediately available for comment. Valeant is no stranger to deal-making. It has for years purchased companies or signed licensing agreements, sometimes using multibillion-dollar debt packages to fund the deals, in order to build out a pipeline of profitable or potentially profitable drugs. Salix, based in Raleigh, NC, is one example. The assets of Seattle-based Dendreon, which filed for Chapter 11 bankruptcy last year, is another. One final note is that EyeGate signed a licensing deal with RXi Pharmaceuticals, a Worcester, MA-based developer of RNA interference treatments, in 2010 to combine RXi’s treatment with EyeGate’s ability to delivery drugs noninvasively. RXi doesn’t appear in EyeGate’s recent regulatory filings.